Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
Notified -
Globe Newswire8-12-2025, 05:30
VoltaGrid Closes $5.0 Billion Comprehensive Financing Package Consisting of $2.0 Billion of Senior Secured Second Lien Notes and $3.0 Billion Asset-Based Loan Facility 10-11-2025, 20:00
